



**VIJAYA
DIAGNOSTIC
CENTRE**®

August 06, 2026

To
The Listing Department,
National Stock Exchange of India Limited
NSE Symbol: **VIJAYA**

To
The Corporate Relations Department,
BSE Limited
BSE Scrip Code: **543350**

Dear Sir/Madam,

Sub: Investor Presentation

Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the presentation on Financial Results for quarter ended June 30, 2026, which would be used in the Investors / Analysts earnings conference call scheduled to be held on **Friday, August 07, 2026, at 10:30 A.M. (IST).**

Please take the information on record.

Thanking you,
For **Vijaya Diagnostic Centre Limited**

TADEPALLI
NAGA VASUDHA

Digitally signed by
TADEPALLI NAGA VASUDHA
Date: 2026.08.06 21:25:17
+05'30'

Naga Vasudha Tadepalli
Company Secretary & Compliance Officer
M. No. A23711

Encl.: As Above



**VIJAYA
DIAGNOSTIC
CENTRE**



Q1 FY27 Earnings Presentation

August 6, 2026

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Vijaya Diagnostic Centre Limited (the ‘Company’)**, have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.



**VIJAYA
DIAGNOSTIC
CENTRE**



Q1 FY27 Performance Snapshot

Financial Performance

INR 2,310 Mn

Revenue from Operations

INR 985 Mn | 42.7%

EBITDA | EBITDA Margin %

INR 531 Mn | 23.0%

PAT | PAT Margin %

Key Metrics



1.24 Mn

Footfall

4.59 Mn

Tests



166 ⁽¹⁾

Centres

92%

B2C Revenue %



YOY Growth %

22.8%

Revenue
Growth %

16.5%

Test Volume
Growth %

12.7%

Footfall
Growth %


34.0%

EBITDA
Growth %


37.6%

PAT
Growth %

Geographical Contribution



Wellness Share%





Commenting on the Q1 FY27 results and future business outlook, Ms. Suprita Reddy, MD & CEO at Vijaya Diagnostic Centre Ltd. said:

“I’m pleased to start on a positive note, as we delivered robust year-on-year revenue growth of approximately 22.8%, supported by volume growth of nearly 16.5% in Q1 FY 27.

Coming to PH, we delivered year-on-year growth of approximately 18%, primarily driven by network expansion.




During the quarter, we further expanded our network with the successful commissioning of 4 spokes across Hyderabad, AP and Pune.

In April, we commissioned a hub centre in Gachibowli, Hyderabad with a 160-slice cardiac CT.




I am pleased to announce that in July, we have also commissioned our flagship hub in Bengaluru located at JP Nagar, where we have introduced advanced imaging technologies, including a digital PET-CT with an in-built cardiac CT and a 75cm wide bore 3T Omega MRI. It also houses full-fledged lab which will serve as the central lab for our entire Bengaluru network.

Our expansion plan for FY27 reflects the next stage of our growth story. We plan to commission 9 hub centres along with 10-12 spoke centres in the next 12 months.”


Key Financials




Revenue Mix




Tests Performed (# in Mn)




Footfalls (# in Mn)




Tests / Footfalls (#)



Revenue per Test (INR)



Revenue per Footfall (INR)



Consolidated Profit & Loss Statement

(INR Mn)

Particulars	Q1 FY27	Q1 FY26	Y-o-Y	Q4 FY26	Q-o-Q	FY26	FY25	Y-o-Y
Revenue from operations	2,309.8	1,880.5	22.8%	2,193.8	5.3%	8,142.0	6,813.9	19.5%
Cost of materials consumed	256.0	214.1	19.5%	249.3	2.7%	946.8	847.6	11.7%
Gross Profit	2,053.9	1,666.4	23.3%	1,944.5	5.6%	7,195.2	5,966.3	20.6%
Gross Profit (%)	88.9%	88.6%	31 bps	88.6%	28 bps	88.4%	87.6%	81 bps
Employee benefits expense	374.8	316.1	18.6%	338.3	10.8%	1,307.4	1,121.5	16.6%
Other expenses	693.7	615.0	12.8%	650.9	6.6%	2,518.4	2,112.6	19.2%
EBITDA	985.4	735.3	34.0%	955.2	3.2%	3,369.4	2,732.2	23.3%
EBITDA Margin (%)	42.7%	39.1%	356 bps	43.5%	-88 bps	41.4%	40.1%	129 bps
Other income	85.3	70.5	21.0%	24.0	255.4%	208.0	183.2	13.5%
Depreciation and amortization expense	251.2	208.9	20.3%	243.3	3.3%	918.2	706.0	30.1%
EBIT	819.5	596.9	37.3%	735.9	11.4%	2,659.1	2,209.4	20.4%
Finance costs	110.0	74.9	47.0%	93.2	18.0%	332.3	267.4	24.3%
Profit before Exceptional Items & Tax	709.4	522.1	35.9%	642.7	10.4%	2,326.8	1,941.9	19.8%
Exceptional Items	0.0	0.0	-	0.0	-	0.0	10.3	-100.0%
Profit before Tax	709.4	522.1	35.9%	642.7	10.4%	2,326.8	1,931.6	20.5%
Tax expenses	178.4	136.2	31.0%	163.4	9.2%	597.0	493.7	20.9%
Profit before Minority Interest	531.0	385.9	37.6%	479.3	10.8%	1,729.8	1,437.9	20.3%
Minority Interest	0.0	0.0	-	0.0	-	0.0	0.0	-
Profit after Tax (PAT)	531.0	385.9	37.6%	479.3	10.8%	1,729.8	1,437.9	20.3%
PAT Margin (%)	23.0%	20.5%	247 bps	21.8%	114 bps	21.2%	21.1%	14 bps
EPS – Basic (INR)*	5.2	3.8	37.5%	4.7	10.8%	16.8	14.0	20.2%

*Not annualized

Sustained Momentum Observed Across the Wellness Segment

1

High Volume of Wellness testing being observed in younger population due to **increased awareness & growing chronic disease burden** due to stress, sedentary life & shift in lifestyle patterns

2

Adoption of wellness testing is scaling across markets, with **Tier 2 and Tier 3 cities** emerging as key growth drivers

3

Digital promotions by the organised players along with third party healthcare platforms have also aided in increased footfalls for wellness packages

4

Faster report turnaround times (TAT), coupled with the **convenience of home testing**, have been key drivers of growth



VIJAYA
DIAGNOSTIC
CENTRE




27.7%

Q1 FY27 YOY Growth %



25.6%

FY26 YOY Growth %






**VIJAYA
DIAGNOSTIC
CENTRE**



Key Developments

1 Launched State-of-the-Art Flagship Hub in JP Nagar, Bengaluru (1/2)

Inaugurated State-of-the-Art Hub in JP Nagar in the 2nd week of July, 2026 in line with our strategy of expanding organically in Bengaluru




10,000+ sq.ft. Hub houses advanced equipment like Wide Bore 3T MRI and Digital PET with 160 slice cardiac CT

The Wide Bore 3T Omega MRI is first of its kind in Karnataka, offering significantly faster scan times while delivering enhanced patient comfort and a superior imaging experience



1 Launched State-of-the-Art Flagship Hub in JP Nagar, Bengaluru (2/2)

Inaugurated State-of-the-Art Hub in JP Nagar in the 2nd week of July, 2026 in line with our strategy of expanding organically in Bengaluru



10,000+ sq.ft. Hub also houses full-fledged lab which will serve as the central lab for entire Bengaluru region

Strategically located in the middle of several super-specialty hospitals

2 Inaugurated a Hub centre in Hyderabad (1/2)

Inaugurated a Hub Centre in Gachibowli, Hyderabad in April, 2026



2 Inaugurated a Hub centre in Hyderabad (1/2)

Inaugurated a Hub Centre in Gachibowli, Hyderabad in April, 2026



3 Inaugurated 2 Spokes in Hyderabad

Inaugurated 2 Spokes in June, 2026 in Hyderabad in line with our strategy of building dense network and deepening marketing penetration



Ramanthapur




Chintalmet



4 Inaugurated 2 Spokes in AP

Inaugurated 2 Spokes in June & July 2026 respectively in AP as part of our strategy to consolidate our presence in Core Geographies



Muralinagar (Vizag)





Magunta Layout (Nellore)



5 Launched a Spoke in Kharadi, Pune

Inaugurated a Spoke in June, 2026 in Kharadi in line with our strategy of expansion in Pune post PH acquisition



Leveraging the Transformative Power of AI for CT KUB Cases Reporting



Automated Stone Detection & 3D Localization

- Auto-locates & measures stones
- Precise 3D localization of stones aids in anatomical orientation



Intelligent Differentiation

- Distinguishes true kidney stones from harmless pelvic vein calcifications and vascular spots in arteries




Improving Radiologist's Productivity & Accuracy

- Prioritises urgent scans - flagging positive cases
- Cuts reporting time with precise volume & density data
- Reduces risk of missing small or faint stones



Enhances Precision Surgical Planning for Urologist

- Precise volume and density data helps in choosing the right intervention
- Accurate "stone burden" calculation allows for better prediction of stone-free rates after a single procedure



Incorporating AI has enhanced the surgical planning experience, and improves operational efficiency across the entire Urology pathway



Original Image





Image With Anatomy And Conditions



- AI dental diagnostics platform delivers **high-precision 2D/3D radiograph analysis, predictive care, and clinical decision support**
- **AI-based 2D & CBCT scan analysis** for faster, more accurate diagnostics
- Enhances **patient outcomes & trust** with **visual decisions support**
- Enables **predictive care & personalized treatment planning**



**VIJAYA
DIAGNOSTIC
CENTRE**




Strategic Expansion

Inorganic Expansion Strategy

- Successfully acquired PH, Pune's largest B2C integrated diagnostic chain
- This strategic acquisition seamlessly aligns with our commitment to providing top-notch healthcare services at affordable price, reflecting our shared cultural values
- Operationalized 2 hubs in Ambegaon & Kalyani Nagar and 2 spokes under Vijaya PH Brand, following the acquisition
- Planning to add 1-2 hubs in the next 12 months

Expansion into Neighbouring State

- Planning to add 3 hubs in FY27 to take our overall hub network to 6 hubs in Karnataka
- Actively scouting for locations to add multiple hubs and spokes in FY28 and FY29



East India Strategy


- Planning to add 1 Hub in the next 12 months to take our overall network to 8 in East India
- Employing our proven hub and spoke model, aim to replicate our success in East India by creating a dense network

Core Market Strategy

- Embracing our hub-and-spoke model, we aim to broaden our presence in concentric circles, strategically reaching Tier 1 and Tier 2 cities within AP and Telangana where our brand is highly esteemed
- Added a hub centre in Hyderabad in Q1 FY27 and planning to enter 2 key cities of AP - Vijayawada & Guntur & add multiple spokes across our core geography in the next 12 months

Expansion Plans - Upcoming Hubs and Spokes Centres

Geography	Launched till date in FY27	Upcoming	Tentative Timelines for Commencement
Hyderabad	1 Hub 3 Spokes	1 Spoke 1 Spoke	H1 FY27 H2 FY27
RoAPT	2 Spokes	1 Hub 1 Spoke 1 Hub	H2 FY27 H2 FY27 H1 FY28
Mysore + Bengaluru	1 Hub	2 Hubs	H2 FY27
West Bengal	-	1 Hub 1 Spoke	H2 FY27 H2 FY27
Pune	1 Spoke	-2 Hub	H2 FY27






**VIJAYA
DIAGNOSTIC
CENTRE**



Company Overview

Vijaya Diagnostic is the largest integrated B2C focused diagnostic chain in India with 166 state-of-the-art centres spread across 27 cities & towns

Evolved from a regional player to a player with presence in multiple geographies ...



... While retaining its core values of providing Quality, Reliable & Accurate Diagnostic services at Affordable prices



40+

Years of Vintage



17 labs with NABL Accreditation

Founded by Mr. Surendranath Reddy in 1981 and currently led by Ms. Suprita Reddy

27

Cities and towns across India



Largest B2C integrated Player in India

350+

Doctors



Radiologist & Pathologist network

~4.82 Mn

Footfalls ⁽¹⁾




Trusted by every Age group

~17.57 Mn

Tests ⁽¹⁾



Most preferred Diagnostic Centre




Complete Range of Diagnostic Services under One Roof


Robust operational network enables us to offer integrated, high-quality diagnostic services that significantly elevate the customer experience




Pathology ⁽¹⁾



Radiology ⁽¹⁾



Vijaya has been successful in creating a dense market consolidating its foothold in its core geographies of AP & Telangana markets




A dense network created across AP & Telangana aids in distributing patient load and offering significantly faster TAT across tests

1. For Q4 FY26

● Existing Centres ● Upcoming Hub in H2 FY27 ● Upcoming Centre in FY28


Strong Traction observed in Newer Geographies (1/3)

Differentiated offering has accelerated Vijaya's success in new geographies




Faster break-even's enable replication of densification strategy in newer geographies

Differentiated offering has accelerated Vijaya Brand's success in new geographies




Pune Network




Faster break-even's enable replication of densification strategy in newer geographies

Strong Traction observed in Newer Geographies (3/3)


Differentiated offering has accelerated Vijaya Brand's success in new geographies



Faster break-even's enable replication of densification strategy in newer geographies




Geographical Revenue Mix



Vijaya is well-placed to attract customers in new geographies due to its integrated offering and strong emphasis on customer experience

Online Services

Enhancing Customer Experience through Seamless Online App, E-Commerce Website and Call Centre Bookings



Access to reports online & historical medical records



Intuitive⁽¹⁾ & user-friendly interface



Agile customer service team





High Brand salience



High customer stickiness



Organic word of mouth growth



Home Collections

Elevating Customer Experience through Home Collections



Seamless & Efficient process



Temperature Controlled Logistics



High standards of hygiene maintained




Pre-sealed & sterilized single-use home kit



Reaches Lab within 2 hours⁽²⁾

Robust Technical Capabilities with State-of-the-art IT Infrastructure



Key Suppliers



- Long standing relationship with medical technology vendors
- At the forefront of introducing new tests by adopting the latest medical technologies
- Among the first diagnostic service provider in South India to offer PET-CT scan in 2008

Advanced Software to Manage Clinical Data



Advance Laboratory Information Management System (LIMS)



Fully Integrated Radiology Information Systems (RIS) and Picture Archive and Communication Systems (PACS)

Front end IT infrastructure enabling...



Standardization across our operations



Closely track key performance metrics and maintain the **Turn-Around Time (TAT)**



Reduce incidence of errors due to **Low Human Intervention**



Monitor Technical Operations



Provide **Uniform Experience** to customers from booking appointments to accessing reports online

Vijaya has been ahead of the curve in getting best-in-class & latest diagnostic equipment in India which has helped in offering high quality services



Founder & Chairman

Dr. S. Surendranath Reddy

- ✓ 40+ years of experience
- ✓ Holds Bachelor's degree in Medicine and Doctor of Medicine in Radiology



Managing Director & CEO

Ms. Suprita Reddy


- ✓ 22+ years of experience
- ✓ Awarded Women Leadership Award in Healthcare by ABP



Executive Director

Mr. Sunil Chandra Kondapally

- ✓ 22+ years of experience
- ✓ Holds Bachelor's degree in Electrical Engineering from Florida State University



Non-Executive Director

Ms. S Geeta Reddy

- ✓ 35+ years of experience
- ✓ BOD at Sura Agritech, Iffco Kisan, Namrata Diagnostics, etc.
- ✓ LLB from Osmania University



Non-Executive Independent Director

Mr. S. Murthy Chavali

- ✓ 35+ years of experience
- ✓ Ex-CEO - Aurigene Discovery Tech
- ✓ MBA from IIM, Bangalore & BTech from IIT, Madras



Non-Executive Independent Director

Mr. Dipinder Singh Sekhon

- ✓ 25+ years of experience
- ✓ Founder of AI Healthcare company iKites.ai
- ✓ MPA from LSE⁽¹⁾
- ✓ BTech & MTech from IIT, Delhi



Non-Executive Independent Director

Dr. Manjula Anagani

- ✓ 25+ years of experience
- ✓ Clinical Director & HOD - Centre of women & childcare - Care hospitals
- ✓ Awarded Padma Shri by GOI



Non-Executive Independent Director

Mr. Ravi Shankararamiah

- ✓ 40+ years of experience and designated as Senior Advocate by High Court of Andhra Pradesh
- ✓ Graduated magna cum laude from USC, LA⁽²⁾ in MS



Non-Executive Independent Director

Dr. Sasikala Paruchuri Kola

- ✓ 30+ years of experience as a Gynaecologist & Obstetrician
- ✓ Leadership roles in FOGSI⁽³⁾ and OGS⁽⁴⁾
- ✓ MD & DGO from Osmania Medical College



Founder & Chairman

**Dr. S. Surendranath
Reddy**



Managing Director & CEO

Suprita Reddy



Executive Director

**Sunil Chandra
Kondapally**



Chief Operating Officer

**Sivaramaraju
Vegesna, CFA**



Chief Financial Officer

Narasimha Raju K.A



Director - Laboratory


Dr. Kiran B



Director - Radiology

Dr. V Vijayanand

Shareholding Pattern as at 30th June, 2026



DIIs: Mutual Funds, AIFs and QIBs

FIIs: Hedge Funds, Sovereign Wealth Funds, Foreign MFs, Pension Funds, Trusts and AMCs

Others: Retail, Bodies Corporate and others



Key Investors

 Free Zoom Webinar  Live on   Vdc Connect  **VIJAYA
DIAGNOSTIC
CENTRE**

Webinar on Liver Elastography

10th April, 2026 (Friday) | 4 PM IST



Chief Guest
Dr. Prashanth Koyyoda
MBBS, MS, MCh
Consultant Surgical
Gastroenterologist,
HPB & Advanced
Laparoscopic Surgeon.



Speaker
Dr. Shubhi Agrawal
MD
Consultant Radiologist,
Vijaya Diagnostic Centre,
Hyderabad.



Moderator
Dr. Vikram Reddy
MBBS, MD, DNB (Radiology)
Consultant Radiologist,
Vijaya Diagnostic Centre,
Hyderabad.

 Free Zoom Webinar  Live on   Vdc Connect  **VIJAYA
DIAGNOSTIC
CENTRE**

Webinar on Breast Emergencies in Radiology

22nd May, 2026 (Friday) | 4 PM IST



Chief Guest
Dr. Pavani Sathineedi
MBBS, MS(OBG), FMAS, FRM
Consultant Gynaecologist,
Aplus Hospitals,
Kurnannapalem.



Speaker
Dr. Abhinaya
MD
Consultant Radiologist,
Vijaya Diagnostic Centre,
Vizag.




Moderator
Dr. K. Lakshmi Srujana
DNB Radiodiagnosis (NIMS).
Consultant Radiologist,
Vijaya Diagnostic Centre,
Vizag.

 Free Zoom Webinar  Live on   Vdc Connect  **VIJAYA
DIAGNOSTIC
CENTRE**

Webinar on Platelet Dynamics Analyzing Quantitative Ranges, Etiologies, and Volumetric Curves

5th June, 2026 (Friday) | 4 PM IST



Speaker
Dr. Vaibhavi
MBBS, MD.
Consultant Pathologist,
Vijaya Diagnostic Centre, Gurgaon.



Moderator
Dr. Suvarna Pai
MBBS, MD Pathology
HOD Hematology,
Vijaya Diagnostic Centre, Hyderabad.

 Free Zoom Webinar  Live on   Vdc Connect  **VIJAYA
DIAGNOSTIC
CENTRE**

Webinar on Tuberculosis

18th June, 2026 (Thursday) | 4 PM IST



Speaker
Dr. Madhavi Kumpati
Senior consultant Microbiology
Vijaya Diagnostic Center, Hyderabad



Moderator
Dr. Vittal
MD Microbiology
HOD, Microbiology at VDC
Vijaya Diagnostic Center, Hyderabad.

Awards & Accolades



**Best Healthcare Brands
2026** recognized by ET Edge



**Most Preferred Workplace
2026-27** recognized by
Marksmen Daily



**Icon in Integrated Diagnostic
Services** by Times Health
Excellence TS & AP 2025



Best Diagnostic Centre
awarded at HMTV Healthcare
Awards 2025



**Icon in Integrated Diagnostic
Services** by Times Health
Excellence 2024 - TS & AP



Best Healthcare Brands' 2025
recognized by ET Edge



**Most Trusted Brand of India
2024-25** awarded by Marksmen
Daily – 4th edition



**Most Preferred Workplace for
Women 2024 – 25** recognized
by Marksmen Daily



**Fastest Growing Brands 2023-
24** awarded at Asian business &
Social Forum 2024, Dubai



Best Healthcare Brands' 2024
recognized by ET Edge



Best Brand awarded at ET Edge
Awards 2023



**Fastest Growing Leaders 2023-
24** awarded at Asian business &
Social Forum 2024, Dubai



Best Healthcare Brands'
awarded by Economic Times -
2023



**Excellence In Comprehensive
Diagnostic Care** awarded by
ABP Ananda Swasthya Samman



Most Trusted Brand of India
awarded by Marksmen Daily –
3rd edition



**VIJAYA
DIAGNOSTIC
CENTRE**



Annexure



State-of-the-art Infrastructure (2/3)




State-of-the-art Infrastructure (3/3)




Advanced Equipment in Place to Deliver High Quality Services (1/2)




Advanced Equipment in Place to Deliver High Quality Services (2/2)




Diagnostic Centre (Nos)




Footfalls (Mn)




Tests Performed (Mn)




Test per Footfall (Nos)



Revenue per Test (INR)




Revenue per Footfall (INR)




Consistent Financial Performance

(INR Mn)


Revenue




EBIDTA




PAT



EBIDTA Margin (%)




PAT Margin (%)




Integrated business model with high B2C concentration (~92%) and a strong brand recall has resulted in Industry leading margins


Surplus Cash (INR Mn)




CFO ⁽¹⁾ / EBIDTA (%)



RoCE Pre-Tax ⁽²⁾ (%)



RoE ⁽³⁾ (%)



1. CFO = Cash flow from Operations

2. ROCE (Pre-tax): (PBIT ex Other income) / (Average Network + Average Long Term Lease Liabilities – Average Surplus Cash)

3. ROE: PAT / Average Network

Consolidated Profit & Loss Account

(INR Mn)

Particulars	FY22	FY23	FY24	FY25	FY26
Revenue from operations	4,624	4,592	5,478	6,814	8,142
Cost of materials consumed	715	589	654	848	947
Employee benefits expense	707	785	902	1,122	1,307
Other expenses	1,165	1,398	1,712	2,113	2,518
EBITDA	2,037	1,820	2,209	2,732	3,369
EBITDA %	44.1%	39.6%	40.3%	40.1%	41.4%
Other income	128	142	208	183	208
Depreciation and amortization expense	527	617	570	706	918
EBIT	1,638	1,344	1,847	2,209	2,659
Finance costs	165	209	240	267	332
Profit before tax and exceptional items	1,474	1,135	1,607	1,942	2,327
Exceptional items	-	-	21	10	-
Profit before Tax	1,474	1,135	1,587	1,932	2,327
Tax expenses	367	283	390	494	597
Profit after Tax before Minority Interest	1,107	852	1,196	1,438	1,730
Minority Interest	10	5.8	8	-	-
Profit after Tax	1,097	846	1,188	1,438	1,730
PAT %	23.7%	18.4%	21.7%	21.1%	21.2%
EPS – Basic (INR)	10.76	8.29	11.62	13.95	16.81

Consolidated Balance Sheet

(INR Mn)

ASSETS	Mar-22	Mar-23	Mar-24	Mar-25	Mar-26
NON-CURRENT ASSETS	4,436	5,777	7,714	9,664	11,851
Property, plant and equipment	1,966	2,940	3,785	4,469	5,625
Capital work-in-progress	341	271	83	703	343
Goodwill	53	53	1,192	1,192	1,192
Other intangible assets	14	22	207	219	204
Right of use asset	1,672	2,223	2,235	2,768	3,672
Intangible assets under development	1	6	5	0	8
Financial assets					
- Investments	0	0	0	0	0
- Other financial assets	75	90	113	165	481
Deferred tax assets	89	83	29	0	0
Income tax assets	2	2	2	12	2
Other assets	223	85	62	136	324
CURRENT ASSETS	2,698	2,757	2,113	3,072	3,219
Inventories	43	20	52	49	49
Financial assets					
- Investments	542	1,390	1,091	1,846	2,284
- Trade receivables	98	95	162	148	209
- Cash and cash equivalents	110	242	222	128	397
- Bank balances other than Cash and cash equivalents	1,813	922	508	361	131
- Loans	0	0	0	0	
- Other financial assets	51	36	31	478	80
Other current assets	41	51	46	62	70
TOTAL ASSETS	7,135	8,534	9,828	12,736	15,070

EQUITY & LIABILITIES	Mar-22	Mar-23	Mar-24	Mar-25	Mar-26
EQUITY	4,695	5,466	6,599	7,991	9,572
Equity share capital	102	102	102	103	103
Instruments entirely equity in nature	-	-	-	-	-
Other equity	4,593	5,364	6,497	7,889	9,469
Non-Controlling Interest					
NON-CURRENT LIABILITIES	1,778	2,406	2,500	3,119	4,260
Financial liabilities					
- Borrowings	0	0	0	0	0
- Lease liabilities	1,703	2,330	2,391	2,964	4,000
- Other financial liabilities	0	0	0	0	0
Provisions	74	71	106	99	110
Other non current liabilities	1	5	3	3	5
Deferred tax liabilities	-	-	-	53	145
CURRENT LIABILITIES	661	662	729	1,626	1,239
Financial liabilities					
- Borrowings	6	0	0	0	0
- Lease liabilities	126	145	201	232	226
- Trade payables	216	277	329	331	376
- Other financial liabilities	248	140	114	925	491
Income tax liabilities	9	24	12	35	9
Provisions	21	40	32	60	83
Other current liabilities	35	36	40	44	53
TOTAL EQUITY AND LIABILITIES	7,135	8,534	9,828	12,736	15,070

Consolidated Cash Flow Statement

(INR Mn)

Particulars	Mar-22	Mar-23	Mar-24	Mar-25	Mar-26
Cash Flow from Operating Activities					
Profit before Tax	1,474	1,135	1,587	1,932	2,327
Adjustment for Non-Operating Items	572	683	599	786	1,070
Operating Profit before Working Capital Changes	2,046	1,818	2,186	2,718	3,397
Changes in Working Capital	-67	90	-14	-74	-168
Cash Generated from Operations	1,979	1,908	2,172	2,644	3,228
Less: Direct Taxes paid	-399	-262	-339	-399	-522
Net Cash from Operating Activities	1,580	1,646	1,833	2,245	2,706
Purchase and construction of property, plant and building (net)	-1,223	-1,248	-880	-955	-1,827
Acquisition of subsidiary	-	-	-1,475	-	-
Investments (net)	-127	734	530	-893	57
Others	120	887	401	29	28
Cash Flow from Investing Activities	-1,231	-1,096	-1,423	-1,819	-1,742
Cash Flow from Financing Activities	-306	-419	-445	-520	-695
Net increase/ (decrease) in Cash & Cash equivalent	44	131	-36	-94	269
Cash & Cash Equivalents at the beginning of the period	67	110	258	222	128
Cash & Cash equivalents at the end of the period	110	242	222	128	397

Surplus Cash

Particulars	Mar-22	Mar-23	Mar-24	Mar-25	Mar-26
Investments*	542	1,390	1,092	1,846	2,284
Cash and cash equivalents	110	242	222	128	397
Bank balances other than Cash and cash equivalents**	1,813	922	537	843	512
Less: Deferred Capital Creditors				750	323
Total	2,465	2,554	1,851	2,067	2,869

*Current investments + investments with maturity more than 12 months (part of other non-current financial assets)

** Includes all the fixed deposits



**VIJAYA
DIAGNOSTIC
CENTRE**

Thank You

For further information please contact:

Mr. Dhiren Gala

Head - Investor Relations & Corporate Development

+91 90598 93206

dhiren.g@vijayadiagnostic.in

ir@vijayadiagnostic.in

www.vijayadiagnostic.com

Corporate Office : #6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India.